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Contemporary results of angioplasty-based
infrainguinal percutaneous interventions
James H. Black, III, MD, Glenn M. LaMuraglia, MD, Christopher J. Kwolek, MD, David C. Brewster, MD,
Michael T. Watkins, MD, and Richard P. Cambria, MD, Boston, Mass
Introduction: Although lower-extremity bypass grafting has been the gold standard for infrainguinal revascularization,
endovascular therapies have been increasingly applied to avoid operative morbidities. This study addresses the initial
results of an implementation of infrainguinal percutaneous transluminal angioplasty (PTA) performed by vascular
surgeons to treat lower-extremity ischemia.
Methods: From January 2002 to July 2003, 95 consecutive patients presenting with the spectrum of lower-extremity
ischemic manifestations, in whom infrainguinal PTA was the initial choice of treatment, were assessed for treatment
efficacy by clinical and noninvasive evaluation. Study end points of angiographic, hemodynamic, and clinical successes
(Society of Vascular Surgery reporting standards) were recorded, and variables associated with ischemic category
improvement were analyzed by univariate and multivariate analysis. During the same study interval, 87 patients
underwent bypass grafting (not further considered).
Results: PTA was used to treat 100 limbs in 95 consecutive patients: 63 limbs (63%) had femoropopliteal PTA, 17 limbs
(17%) had tibioperoneal PTA, and 20 limbs (20%) had multilevel PTA. Tissue-threatening ischemia was present in 47%
of patients, and 53% were treated for claudication. Complications (no mortality) included one myocardial infarction (1%)
and two access site hematomas (2%). Angiographic and hemodynamic success (a .10 increase in ankle-brachial index) was
obtained in 97% and 90% of the treated limbs, respectively. With a mean follow-up of 14 months, clinical success was
obtained in 85% of the treated limbs, and limb salvage for critical ischemia was achieved in 75% (30/40 limbs). Of the
PTA failures, five patients (5%) underwent bypass grafting, and five patients (5%) underwent major amputation because
of no further reconstructive options or extensive necrosis. Insulin-dependent diabetes mellitus (risk ratio [RR], 3.1; 95%
confidence interval [CI], 1.1 to 8.7, P .02), poor runoff into the foot (RR, 3.7; 95% CI, 1.6 to 8.6, P .001), and renal
insufficiency (serum creatinine >1.5 mg/dL ) (RR, 3.7; 95% CI, 1.8 to 7.6, P  .001) were predictive of PTA failure.
Conclusion: Infrainguinal percutaneous transluminal angioplasty for lower-extremity ischemia is feasible, safe and
provides acceptable hemodynamic and clinical results. PTA will become the initial treatment for most patients requiring
lower-extremity revascularization. (J Vasc Surg 2005;42:932-9.)Lower-extremity ischemia secondary to peripheral ar-
terial occlusive disease is a marker for cardiovascular mor-
tality and treatment thereof is associated with substantial
morbidity, mortality, and expenditure of health care re-
sources.1-3 Surgical bypass grafting, considered the gold
standard of treatment, has produced favorable results with
5-year limb salvage rates of 80%.4-6 However, related to
both frequently associated coronary associated disease and
the extent and limitations of the surgery itself, systemic and
local complications occur in up to 25% of patients.7-11
Furthermore, the morbidity associated with surgical revas-
cularization may compromise functional outcomes, as
50% patients report a return to normal functional status
by 6 months.12
In consideration of the aforementioned morbidity, per-
cutaneous transluminal angioplasty (PTA) has been pro-
posed as an alternative to traditional surgical approaches
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932to lower-extremity ischemia. In addition, when patients
present with failure of conservative therapy for claudica-
tion, PTA has enjoyed increasing favor as a first-line modal-
ity in the relief of claudication, despite variable patency
rates and considerable expense.13-16
A variety of factors referable to vascular anatomy or
clinical presentation have been correlated with the early
success of PTA and likely contribute significantly to the
broad range of reported treatment results.17,18 Enthusiasm
for PTA in supplanting surgery as first-line treatment for
native infrainguinal disease producing lower-extremity
ischemia is based upon its safety, technical feasibility, and
the rare occurrence that a failed PTA would preclude
subsequent surgical bypass grafting has been well docu-
mented in the literature. Indeed, a recent report with
long-term follow-up has documented the equivalent need
for re-interventions between surgical and endovascular
therapies.19 Therefore, the goal of the present study was
the review of initial results of a application of PTA for all
clinical grades of infrainguinal native arterial disease by
endovascular surgeons and attempt to identify anatomic
and comorbid factors that may predict PTA failure.
METHODS
The experimental protocol was approved by the Insti-
tutional Review Board of the Harvard Medical School and
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study interval (January 2002 until July, 2003), consecutive
male and female patients treated for claudication or limb-
threatening ischemia, in whom infrainguinal percutaneous
transluminal angioplasty (PTA) was the initial choice of
treatment of native arterial lesions, were accrued into a
database for study.
During the study interval, 95 patients underwent PTA
for native arterial lesions, with 100 limbs treated. During
the same interval, 87 patients underwent surgical bypass
grafting (not further considered). The follow-up period
extended from January 2002 until January 2004. The
decision of which patients could be treated by initial PTA
was predicated on the clinical examination, anatomic eval-
uation, and judgment of the staff endovascular surgeon
involved. Those patients with either immediate need for
revascularization (acute ischemia category IIb20) or a func-
tionally useless limb were excluded; patients clinically diag-
nosed with acute ischemia from embolic events were
treated with open surgical embolectomy. Also excluded
from analysis were those patients in whom the PTA in-
cluded concomitant suprainguinal procedures (iliac or aor-
tic angioplasty), angioplasty of vein or polytetrafluoroeth-
ylene bypass graft lesions, use of rheolytic or mechanical
thrombectomy, atherectomy, and thrombolysis.
The database included demographic information, car-
diovascular risk factor profile, clinical presentation (Ruth-
erford category 1 to 6/Society for Vascular Surgery Re-
porting Standard21), lesion characteristics (Trans-Atlantic
Inter-Society Consensus [TASC] classification for femoro-
popliteal lesions), and preprocedure and postprocedure
hemodynamics by ankle-brachial indices (ABI), pulse vol-
ume recordings, or both.
PTA technique. All procedures were performed in an
angiographic suite (83%) or an endovascular operating
room with a fixed imaging system (17%). None of the
procedures used a portable imaging system. Under local
anesthesia, the PTA technique used a contralateral, retro-
grade, common femoral artery approach for full diagnostic
imaging of the ischemic extremity, and in patients with
preprocedure imaging (magnetic resonance or computed
tomography angiography) in whom no proximal femoral
intervention was planned, an ipsilateral, antegrade com-
mon femoral artery approach was undertaken. Infrapopli-
teal level PTA was performed exclusively via an ipsilateral,
antegrade approach. No popliteal artery punctures were
employed as vascular access. Left brachial access was used
when femoral access was not technically feasible because of
occlusion or scarring from prior surgical procedures.
Iodinated contrast was used in patients with normal
renal function and gadolinium in those with renal insuffi-
ciency. Heparin was administered intravenously, and acti-
vated clotting times were monitored.
Lesions were crossed with platinum-tipped (.018 or
.014 inch) or hydrophilic wires (.035, .018, or .014 inch) as
needed, and noncompliant angioplasty balloons equal to
lesion length were inflated to 4 to 12 atm for 60 seconds.
Use of long angioplasty balloons was avoided to preventintimal injury in adjacent segments free of significant dis-
ease. Subintimal angioplasty techniques were not inten-
tionally used.
Residual lesions (20%) were routinely dilated with
progressively larger-diameter balloons to reach diameters
equal to the intended diameter of the adjacent nondiseased
segment. Postangioplasty dissections in the native arterial
tree were similarly treated by repeat angioplasty. Stenting
was not performed routinely, even for occlusions, unless a
flow-limiting dissection or stenosis could not be treated
adequately by serial balloon dilations.
The relevant angiographic data for each limb were
recorded by the operator for further analysis; femoropopli-
teal lesions were quantitated and classified according to the
TASC,22 and tibial vessel runoff was recorded as the num-
ber of vessels patent into the foot. The total number of
native arterial lesions and number of lesions treated was also
reported. Postprocedure, all patients were treated with 300
mg of clopidogrel (if not previously prescribed) and main-
tained on 75 mg/day for 6 to 8 weeks. All patients also
received 325 mg of aspirin on the day of the procedure and
indefinitely.
Follow-up. Follow-up included gradation of symp-
toms, clinical examination, and arterial noninvasive mea-
surement. Arterial noninvasive measurement included ABI
and pulse volume recordings. For patients with noncom-
pressible vessels, pulse volume recordings were themost com-
monly used modality of hemodynamic follow-up. Follow-up
arterial noninvasive measurement was performed within 1
to 2 months of PTA and again between 6 and 12 months in
concert with clinical examination.
Definitions and end points. Angiographic success in
PTA was recorded when all technically accessible lesions
were treated with a20% residual stenosis remaining in any
given lesion. Hemodynamic success was tabulated accord-
ing to an ABI increase of at least .10, or in patients with
noncompressible vessels, improvement in a plethysmo-
graphic tracing by at least 5 mm, in accordance with pub-
lished reporting standards.20 Clinical success was defined as
an improvement of least one clinical category with demon-
strable hemodynamic success; for those patients with actual
tissue loss who underwent PTA, clinical success required
moving up at least two clinical categories to at least reach a
level of claudication and healed ulcers/gangrene with de-
monstrable hemodynamic success, as defined by the pub-
lished reporting standards.20 Limb salvage required (1) no
major amputation, (2) an expected toe or transmetatarsal
amputation was performed and healed, or (3) ischemic
ulcers had complete healing.20 Secondary end points in-
cluded periprocedural complications and vascular-related
events in the treated limb, such as amputation, need for
another PTA or surgical procedure, or recurrence of ulcers.
Statistics. Data were entered into an Excel spread-
sheet (Microsoft, Inc, Redmond, Wash). Statistical analysis
was performed by transferring data to GraphPad InStat
statistics software (GraphPad Software, Inc, San Diego,
Calif). Univariate influence of dichotomous variables on clin-
ical category improvement was determined using Fischer’s
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(OR) were based on the approximation of Katz in univari-
ate analysis. In addition, all risk ratios (RR) were reported
with 95% confidence intervals (CI). Multivariate logistic
regression models were constructed by including all vari-
ables that were significant at the P  .05 level. Kaplan-
Meier estimates were used to examine limb salvage for
patients presenting with critical ischemia and cumulative
clinical success rates for vascular events across the overall
study population.
RESULTS
Demographics and clinical characteristics are summa-
rized in Table I. The mean pre-PTA ABI was .61  .16.
Hemodynamic success was obtained in 90 (90%) of 100
limbs, as defined by an increase in ABI by .10, or in those
patients with noncompressible vessels, an increase in a
plethysmographic tracing of 5 mm or 50% over the pre-
PTA tracing. The mean post-PTA ABI was .89 .14, for a
mean increase of .28  .14. The hemodynamic and angio-
graphic characteristics of the study population are summa-
rized in Table II. Angiographic success, defined as the
ability to cross and dilate all significant lesions to 20%
residual stenosis, was achieved in 97 of 100 limbs.
Complications. During PTA, minor complications
occurred in four patients (4.2%) comprising flow-limiting
arterial dissection in two patients (2.1%) and one patient
Table I. Demographic and clinical data
Characteristic N (%) Mean  SD
Age (years) — 71.0  10.7
Gender
Male 61 (64.2)
Female 34 (35.8)
Risk factors
Heart disease 44 (46.3)
Hypertension 80 (84.2)
Diabetes mellitus 62 (65.2)
Smoking 62 (65.2)
Hypercholesterolemia 77 (81.1)
Renal insufficiency*/
dialysis dependence 30 (31.5)/8 (8.4)
Number of risk factors
0 0 (0)
1 5 (5.2)
2 30 (31.5)
3 41 (43.2)
4 21 (22.1)
Clinical category of treated
limb†
1. Mild claudication 4 (4.0)
2. Moderate claudication 19 (19.0)
3. Severe claudication 28 (28.0)
4. Ischemic rest pain 10 (10.0)
5. Minor tissue loss 31 (31.0)
6. Major tissue loss 8 (8.0)
Mean clinical category 3.81  1.07
*Serum creatinine 1.5 mg/dL.
†From reference 20.each had embolism (1.0%) and arterial rupture (1.0%).These intraprocedural complications were treated by endo-
vascular methods. The flow-limiting arterial dissections
occurred in the superficial femoral artery and were treated
initially with repeat angioplasty. Because of a persistent
flow-limiting dissection, one of these patients required
placement of a self-expanding nitinol stent (the only fem-
oral stent placed in the series). The arterial rupture oc-
curred in a severely diseased posterior tibial artery and was
treated with temporary balloon occlusion without further
incident. The arterial embolism to the dorsalis pedis artery
occurred after anterior tibial angioplasty and was treated by
short-term thrombolysis and repeat angioplasty without
distal ischemic changes.
No deaths occurred secondary to the PTA procedure.
Local or systemic complications occurred in three patients
(3.3%). One patient developed angina in the angiography
suite and was subsequently diagnosed with myocardial
infarction by serum markers, underwent a thallium stress
test felt to be nonthreatening, and was discharged unevent-
fully 2 days postprocedure. A second patient undergoing
femoral intervention developed a brachial artery hematoma
that was managed expectantly because a contralateral trans-
femoral access was not technically feasible. The last patient
developed a femoral hematoma after sheath removal and
required open surgical repair of a femoral pseudoaneurysm;
this patient was discharged from the hospital 5 days after
the PTA.
Follow-up. Mean duration of follow-upwas 14months
(range, 3 to 24months).Cumulative overall clinical success of
PTA was demonstrated in 86 of 100 limbs (86.5% cumu-
Table II. Angiographic and hemodynamic features of
100 limbs
N (%)
Lesion level
Femoropopliteal 63 (63.0)
Tibioperoneal 17 (17.0)
Multilevel (FP & TP) 20 (20.0)
TASC classification (63 femoropopliteal lesions)*
A 13 (20.6)
B 22 (34.9)
C (3-5 cm occlusion or diffuse disease) 20 (31.7)
D (5cm occlusion) 8 (15.8)
Total Occlusions (of any length) 25 (25.0)
Runoff vessels†
Mean  SD 1.89  0.91
Number of lesions treated
1 23 (23.0)
2 25 (25.0)
3 52 (52.0)
Ankle-brachial index
Pre-PTA .61  .16
Post-PTA .89  .14
Mean increase .28  .14
TASC, Trans-Atlantic Inter-Society Consensus; PTA, percutaneous translu-
minal angioplasty.
*From reference 22.
†Runoff vessel included if 50% stenosis and reaches ankle.lative clinical patency) a s depicted in Fig 1. In the mean
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was achieved in 37 of 49 limbs treated for critical isch-
emia (77.6% cumulative limb salvage rate) by PTA (Fig
2). Of the 10 PTA failures in the setting of critical
ischemia, five patients (5.2%) underwent surgical bypass
grafting with resultant limb salvage and five patients (5%)
underwent major amputation, yielding an overall limb
salvage rate of 88.1%. The presentation, risk profile, and
lesion characteristics for these patients are summarized in
Table III.
For the overall study population, clinical risk factors
and angiographic characteristics potentially associated with
PTA failure were analyzed by univariate analysis and are
summarized in Table IV. The comorbidities of coronary
artery disease, chronic obstructive pulmonary disease, and
smoking did not influence PTA success or failure (results
not shown). Insulin-dependent diabetes mellitus was asso-
ciated with a significantly increased probability of PTA failure
(P  .02, RR, 3.1; 95% CI, 1.1 to 8.7), as was renal insuffi-
ciency, defined as serum creatinine 1.5 mg/dL (P  .001,
RR, 3.7; 95% CI, 1.8 to 7.6).
Increasing complexity of femoropopliteal lesions was
not a reliable predictor of PTA failure, as results of TASCA,
B lesions vs TASC C, D lesions did not reach significance
(P  .17, and P  .28, respectively). Runoff status was
strongly associated with failure of PTA; those patients with
one or no tibial runoff to the foot faired significantly worse
than those with better runoff (P  .001, RR, 3.7; 95% CI,
1.8 to 7.6). After multivariate analysis, runoff status (P 
.03, RR, 2.8; 95% CI, 1.6 to 8.1) and renal insufficiency
(P  .02, RR, 3.3; 95% CI, 1.7 to 6.5) maintained statis-
Fig 1. Cumulative freedom from vascular events in percutaneous
transluminal angioplasty (PTA) limbs, including avoidance of clin-
ical category decrement, need for another PTA, or need for surgi-
cal bypass or major amputation. Dashed line indicates SE 10%.tical significance.DISCUSSION
The impetus for the present study was to review treat-
ment results of critical limb ischemia in the context of an
implementation of PTA performed by surgeons. Although
most vascular surgeons consider lower-extremity bypass
grafting the preferred treatment for most infrainguinal
disease, considerable disagreement remains on themerits of
PTA. The only multicenter, randomized trial of PTA vs
surgery was performed by Wolf et al23 through a Veterans
Administration Cooperative Trial. However, as the popu-
lation was largely claudicants, guidelines regarding the
application to other clinical grades of lower-extremity isch-
emia have not been forwarded from this series. Further-
more, disparate perspectives on the application of PTA
between surgeons and radiologists were highlighted in a
recent British study.24
Fundamentally, such clinical decisionmaking involves a
common debate in vascular interventions—namely a po-
tential trade-off in the durability of lower-extremity bypass
for a substantial reduction in procedural morbidity and
rapid return of functional status linked with PTA. As such,
our group sought additional training to become competent
with catheter-based therapies. The current results would
indicate that the application of catheter-based therapies for
patients presenting with all clinical grades of ischemia can
lead to acceptable results with minimal procedural compli-
cations.
As reported herein, the comparative risk/benefit ratio
of PTA is favorable, indeed to a dramatic extent. The
overall success of our application of PTA in the treatment of
lower-extremity occlusive disease compares favorably with
the published series (Table V). Our current result of 97%
angiographic and 90% hemodynamic success lends cre-
Fig 2. Kaplan-Meier life table analysis of limb salvage in patients
with initial presentations of clinical ischemia. Dashed line indicates
SE 10%. PTA, Percutaneous transluminal angioplasty.dence to the body of literature detailing the technical
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low associated morbidity.
The use of PTA in the treatment of critical limb isch-
emia is drawing attention as a reasonable therapeutic op-
tion. The minimally invasive nature of PTA makes it an
attractive option in a patient unfit for operation or in those
patients lacking adequate autogenous bypass graft conduit.
Furthermore, those patients with critical limb ischemia who
Table III. Failure of PTA in patients treated for critical is
Pt Age/Sex Complaint
TASC
class*/Runoff† Procedure
1 85 M DM ulcer NA/1 PT PTA
2 93 F gangrene C/0 SFA, POP PTA
3 73 F DM ulcer D/1 SFA, POP PTA
4 73 M DM ulcer C/1 CFA, SFA, POP
5 62 M DM ulcer B/2 SFA, POP PTA
6 76 M DM ulcer C/1 SFA, POP, PER P
7 62 M DM ulcer B/2 SFA, POP PTA
8 77 M DM ulcer B/1 SFA, POP, PER P
9 82 M DM rest pain D/1 PFA PTA
0 44 M DM ulcer NA/1 AT, DP PTA
TASC, Trans-Atlantic Inter-Society Consensus; DM, diabetes mellitus; P
below-knee amputation; SFA, superficial femoral artery; POP, popliteal arter
amputation; PER, peroneal artery; AT, anterior tibial artery; DP, dorsalis p
*TASC Classification from reference 22.
†Runoff defined as number of vessels patent into foot with 50% stenosis.
Table IV. Univariate analysis of variables associated with
clinical category status*
No (N  85 limbs)
Category  1 to 3
N (%)
Age 70 41 (51)
Male 49 (61)
IDDM 40 (50)
SCr 2.5 mg/dL 9 (11)
TASC A, B 33 (51)
TASC C, D 29 (45)
Poor runoff† 20 (25)
PTA, Percutaneous transluminal angioplasty; IDDM, insulin-dependent
Consensus.
*Clinical category status scoring according to SVS reporting standard.
†Poor runoff defined as 1 or no tibial vessel patent to foot.
Table V. Comparative results of published series of percu
Series Pts (N) % CLI
Black, 2004 95 47
Surowiec, 200427 300 34 
Molloy, 200315 110 100 
Schillinger, 200339 518 28 
Becquemin, 200331 112 22 
CLI, critical limb ischemia; NA, not applicable.undergo successful revascularization appear to have betterquality of life and survival.25,26 Our study population in-
cluded 49 limbs (49% of total limbs) with critical limb
ischemia. At a mean 14-month follow-up, limb salvage was
achieved in 37 of 49 critically ischemic limbs (77.6% cumu-
lative limb salvage rate).
In agreement with Molloy et al,15 we concluded that
PTA approaches do not preclude secondary surgical revas-
cularization to salvage the limb. In their series, 13 (54%) of
ia
Time to fail
(weeks) Mechanism Outcome
20 foot sepsis BKA
30 toe sepsis BKA
6 foot sepsis BKA, refused surgery
10 foot sepsis surgical bypass with salvage
3 nonhealing ulcer surgical bypass with salvage
25 foot sepsis AKA
16 nonhealing ulcer surgical bypass with salvage
16 foot sepsis surgical bypass with salvage
2 persistent rest pain surgical bypass with salvage
10 non-healing ulcer BKA (no BPG option)
sterior tibial artery; PTA, percutaneous transluminal angioplasty; BKA,
, common femoral artery; PFA, profunda femoral artery;AKA, above-knee
tery; NA, not applicable as lesion not SFA; BPG, bypass graft.
taneous transluminal angioplasty failure to improve
PTA failure
Yes (N  15 limbs)
P (RR; 95% CI)
Category  0 to 3
N (%)
11 (55) .80
12 (60) 1.0
16 (80) .02 (3.1; 1.1-8.7)
9 (45) .001 (3.7; 1.8-7.6)
5 (29) .17
6 (35) .28
13 (65) .001 (3.7; 1.6-8.6)
tes mellitus; SCr, serum creatinine; TASC, Trans-Atlantic Inter-Society
us transluminal angioplasty for infrainguinal disease
One-year %
clinical patency
Follow-up
(months)
Morbidity
(%)
70.2 12 3.0
72.9 8 NA
67 15 3.8
61 12 6.0
68 12 6.3chem
PTA
TA
TA
T, po
y;CFA
edis arpercu
diabetaneo24 angioplasty failures went on to surgical bypass. Indeed,
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on to successful surgical bypass (Table III), for a secondary
limb salvage rate of 88.1%. Clearly, PTA and surgical revas-
cularization can be used as sequential (if needed) rather
than comparative modalities and need not be mutually
exclusive.
Technical components of PTA procedures remain in
evaluation, and a plethora of adjuncts and techniques have
been applied in an effort to improve the historically poor
results, in particular with extensive occlusive disease of the
superficial femoral artery. We used a primarily angioplasty-
based approach, deploying stents in 5% of patients (all
placed in the superficial femoral artery), generally in cases
where inadequate luminal diameter could not be achieved
by angioplasty alone or a flow-limiting dissection was
present.
Randomized trials have failed to show benefit for rou-
tine (vs selective) stenting in endovascular treatment of the
superficial femoral artery.30,31 Clearly our study does not
address the merits of alternative techniques such as subin-
timal angioplasty.32,33 Presently, our posture is to avoid
stenting of the treated vessel by relying on repeated or
longer inflations of the angioplasty balloon to reduce resid-
ual stenoses or luminal defects.
Angiographic characteristics are often implicated as
prime determinants of PTA success. A recent series by
Surowiec et al 27 in reference to superficial femoral artery
angioplasty strongly correlated TASC lesion type with pri-
mary patency. Similarly, Lofberg et al28 studied 92 patients
with critical ischemia and found that if the superficial fem-
oral artery occlusion was 5 cm, 5-year primary patency
was significantly less than that in 5-cm occlusions.
In our examination of lesion complexity and lesion
length of femoropopliteal disease by TASC classification,
we found TASC A, B or TASCC, D did not reliably predict
PTA failure, although the total number of limbs treated in
the our study per category is small. Nonetheless, this is in
agreement with the Society of Cardiovascular and Interven-
tional Radiology (SCVIR) Transluminal Angioplasty and
Revascularization Registry (STAR), as TASC B vs TASC C
did not predict long-term outcome of femoropopliteal
angioplasty.18
Given these findings, TASC classification of lesion type
and length has become less favored as an indication for
surgical revascularization, and our statistical analysis would
support such a posture. Thus, we continue to apply PTA to
TASC C and TASC D lesions. However, given our study
population of 28 limbs with TASC C or TASC D lesion
complexity, it is possible such a conclusion may represent
type II error. Longer follow-up will likely allow firmer
conclusions regarding the appropriateness of treating these
lesions with first line PTA vs surgical revascularization.
By multivariate analysis, the only angiographic param-
eter that predicted PTA failure was poor runoff, defined as
one or no patent tibioperoneal vessels to the ankle or
foot. The association of adequate tibioperoneal runoff
and PTA success is well documented.17,29 In our overall
population, 37 limbs (37%) underwent tibioperoneal an-gioplasty as the only level of PTA in an effort to improve
runoff. In our limb salvage cohort, four of 10 PTA failures
underwent infrapopliteal level intervention with three of
these four having hemodynamic success. Despite hemody-
namic improvement, all went on to fail, highlighting the
potential necessity for distal bypass grafting in selected
patients with tissue loss and severely compromised infra-
popliteal circulation (diffusely diseased single vessel or oc-
cluded segments of tibioperoneal vessels).
Our finding of diabetes mellitus and renal insufficiency
being powerful predictors of PTA failure echoes the current
literature. Renal failure has consistently been shown to be a
powerful predictor of poor outcome after surgical revascu-
larization.34,35 Because of the limited life expectancy and
attendant comorbidities of surgery in this population, PTA
has been advocated as the best option in dialysis-dependent
patients; a position with which we concur. Despite the
conflicting reports in the literature,6,36 our experience with
bypass grafts in dialysis-dependent patients has been poor,
thus we pursue PTA options to extremes as short-term
outcomes are the focus in such patients.
Diabetes mellitus was present in 65% of our patients (a
much greater percentage than other PTA series); yet of our
10 PTA failures, nine patients were diabetic, and all nine
patients had tissue loss. While small numbers in the current
study preclude definitive statements about the prognostic
implications of diabetes mellitus and tissue loss, the associ-
ation of diabetes with early PTA failure is clear from this
review.
The presentation of tissue loss and severely compromised
tibioperoneal runoff in diabetic patients may represent a situ-
ation not easily rectified with percutaneous techniques. Our
data would support a strategy of comprehensive revasculariza-
tion, possibly surgical, as the best initial option in diabetic
patients with advanced ischemia and tissue loss.37 In this
subset of patients, if adequate autogenous conduit is not
available for distal grafting, then the only option may be
percutaneous. An aggressive strategy of concomitant fem-
oropopliteal and tibioperoneal angioplasty may be needed
in this instance to restore adequate perfusion to the foot.
We have noted a failure to restore a pulsatile pulse-volume
recording at the transmetarsal level in some of the failed
PTA patients.
The limitations of this study are its retrospective nature,
potential for referral bias given single institution experience,
and relatively short follow-up. Although short follow-up is
an inherent limitation and inevitably, primary patency will
deteriorate with longer follow-up, failures after PTA—
particularly for complex or extensive lesions or in patients
with limb threat (overall 75% of our patients)—cluster in
the first 6 to 12 months after intervention.16,17,38 Thus, the
mean 14-month follow-up reported herein should encom-
pass most of the treatment failures.
Finally, this report does not address the comparative
application of surgical bypass grafting vs PTA; we utilized
the latter when anatomically feasible, with favorable results.
An equivalent number of patients underwent surgical by-
pass grafting over the study interval because the disease,
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threshold judgment is likely to shift with additional experi-
ence, and we noted a 34% decrease in leg bypasses per-
formed at our institution over the study interval.
CONCLUSION
We believe infrainguinal percutaneous transluminal an-
gioplasty is feasible, safe and provides more-than-acceptable
hemodynamic and clinical results. Avoiding the morbidity
of surgical bypass grafting will be an attractive alternative
for many patients. Particularly as more vascular surgeons
acquire endovascular skills, percutaneous revascularization
techniques will assume more importance as an initial treat-
ment strategy for most of the patients requiring lower
extremity revascularization.
REFERENCES
1. Hunink MG, Wong JB, Donaldson MC, Meyerovitz MF, de Vries J,
Harrington DP. Revascularization for femoropopliteal disease. A deci-
sion and cost-effectiveness analysis. JAMA 1995;274:165-71.
2. Ouriel K, Veith FJ, Sasahara AA. A comparison of recombinant uroki-
nase with vascular surgery as initial treatment for acute arterial occlusion
of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS)
Investigators. N Engl J Med 1998;338:1105-11.
3. Yeager RA, Moneta GL, Taylor LM Jr, Hamre DW, McConnell DB,
Porter JM. Surgical management of severe acute lower extremity isch-
emia. J Vasc Surg 1992;15:385-91; discussion 392-3.
4. Akbari CM, Pomposelli FB Jr, Gibbons GW, Campbell DR, Pulling
MC, Mydlarz D, et al. Lower extremity revascularization in diabetes:
late observations. Arch Surg 2000;135:452-6.
5. Faries PL, Logerfo FW, Arora S, Hook S, PullingMC, Akbari CM, et al.
A comparative study of alternative conduits for lower extremity revas-
cularization: all-autogenous conduit versus prosthetic grafts. J Vasc
Surg 2000;32:1080-90.
6. Ramdev P, Rayan SS, Sheahan M, Hamdan AD, Logerfo FW, Akbari
CM, et al. A decade experience with infrainguinal revascularization in a
dialysis-dependent patient population. J Vasc Surg 2002;36:969-74.
7. Goshima KR, Mills JL Sr, Hughes JD. A new look at outcomes after
infrainguinal bypass surgery: traditional reporting standards systemati-
cally underestimate the expenditure of effort required to attain limb
salvage. J Vasc Surg 2004;39:330-5.
8. L’Italien GJ, Cambria RP, Cutler BS, Leppo JA, Paul SD, Brewster DC,
et al. Comparative early and late cardiac morbidity among patients
requiring different vascular surgery procedures. J Vasc Surg 1995;21:
935-44.
9. Perler BA. Cost-efficacy issues in the treatment of peripheral vascular
disease: primary amputation or revascularization for limb-threatening
ischemia. J Vasc Interv Radiol 1995;6(6 Pt 2 Su):111S-5S.
10. Treiman GS, Copland S, Yellin AE, Lawrence PF, McNamara RM,
Treiman RL.Wound infections involving infrainguinal autogenous vein
grafts: a current evaluation of factors determining successful graft
preservation. J Vasc Surg 2001;33:948-54.
11. Abbruzzese TA, Havens J, BelkinM, DonaldsonMC,Whittemore AD,
Liao JK, et al. Statin therapy is associated with improved patency of
autogenous infrainguinal bypass grafts. J Vasc Surg 2004;39:1178-85.
12. Gibbons G, Burgess AM, Guadagnoli E, Pomposelli FB, Freeman DV,
Campbell DR, et al. Return to well being and function after infraingui-
nal revascularization. J Vasc Surg 1995;21:35-45.
13. Adar R, Critchfield GC, Eddy DM. A confidence profile analysis of the
results of femoropopliteal percutaneous transluminal angioplasty in the
treatment of lower-extremity ischemia. J Vasc Surg 1989;10:57-67.
14. Motarjeme A. PTA and thrombolysis in leg salvage. J Endovasc Surg
1994;1:81-7.
15. Molloy KJ, NasimA, LondonNJ, Naylor AR, Bell PR, Fishwick G, et al.
Percutaneous transluminal angioplasty in the treatment of critical limb
ischemia. J Endovasc Ther 2003;10:298-303.16. Parsons RE, Suggs WD, Lee JJ, Sanchez LA, Lyon RT, Veith FJ.
Percutaneous transluminal angioplasty for the treatment of limb threat-
ening ischemia: do the results justify an attempt before bypass grafting?
J Vasc Surg 1998;28:1066-71.
17. Cambria RP, Faust G, Gusberg R, Tilson MD, Zucker KA, Modlin IM.
Percutaneous angioplasty for peripheral arterial occlusive disease. Cor-
relates of clinical success. Arch Surg 1987;122:283-7.
18. Clark T, Groffsky JL, SoulenMC. Predictors of long-term patency after
femoropopliteal angioplasty: results from the STAR Registry. J Vasc
Interv Radiol 2001;12:923-33.
19. Jamsen TS, Manninen HI, Tulla HE, Jaakkola PA, Matsi PJ. Infrain-
guinal revascularization because of claudication: total long-term
outcome of endovascular and surgical treatment. J Vasc Surg 2003;
37:808-15.
20. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et
al. Recommended standards for reports dealing with lower extremity
ischemia: revised version. J Vasc Surg 1997;26:517-38.
21. Ahn SS, Rutherford RB, Becker GJ, Comerota AJ, Johnston KW,
McClean GK, et al. Reporting standards for lower extremity arterial
endovascular procedures. Society for Vascular Surgery/International
Society for Cardiovascular Surgery. J Vasc Surg 1993;17:1103-7.
22. Dormandy JA, Rutherford RB. Management of peripheral arterial
disease (PAD). TASC Working Group. TransAtlantic Inter-Society
Concensus (TASC). J Vasc Surg 2000;31(1 Pt 2):S1-S296.
23. Wilson S, Wolf GL, Cross AP, The Principal Investigators of Veterans
Administration Cooperative Study No 199. Percutaneous transluminal
angioplasty versus operation for peripheral arteriosclerosis: Report of a
prospective randomized trial in a selected group of patients. J Vasc Surg
1989;9:1-9.
24. Bradbury A, Wilmink T, Lee AJ, Bell J, Prescott R, Gillespie I, et al.
Bypass versus angioplasty to treat severe limb ischemia: factors that
affect treatment preferences of UK surgeons and interventional radiol-
ogists. J Vasc Surg 2004;39:1026-32.
25. Kalra M, Gloviczki P, Bower TC, Panneton JM, Harmsen WS, Jenkins
GD, et al. Limb salvage after successful pedal bypass grafting is associ-
ated with improved long-term survival. J Vasc Surg 2001;33:6-16.
26. Klevsgard R, Risberg BO, ThomsenMB, Hallberg IR. A 1-year follow-up
quality of life study after hemodynamically successful or unsuccessful
surgical revascularization of lower limb ischemia. J Vasc Surg 2001;33:
114-22.
27. Surowiec SM, Davies M, Illig KA, Shortell CK, Rhodes JM, Lee DE, et
al. Percutaneous angioplasty and stenting of the superficial femoral
artery. Society for Vascular Surgery. Anaheim, CA, 2004.
28. Lofberg AM, Karacagil S, Ljungman C, Westman B, Bostrom A,
Hellberg A, et al. Percutaneous transluminal angioplasty of the femo-
ropopliteal arteries in limbs with chronic critical lower limb ischemia. J
Vasc Surg 2001;34:114-21.
29. Johnston K. Femoral and popliteal arteries: reanalysis of results of
balloon angioplasty. Radiology 1992;183:767-71.
30. Vroegindeweij D, Vos LD, Tielbeek AV, Buth J, vd Bosch HC. Ballon
angioplasty combined with primary stenting versus balloon angioplasty
alone in femoropopliteal obstructions: A comparative randomized trial.
Int Angiol 1997;18:251-5.
31. Becquemin J, Favre JP, Marzelle J, Nemoz C, Corsin C, Leizorovicz A.
Systematic versus selective stent placement after superficial femoral
artery balloon angioplasty: A multicenter prospective randomized
study. J Vasc Surg 2003;37:487-94.
32. Balas PE. Subintimal angioplasty in lower limb ischemia: a vascular
surgeon’s view. J Endovasc Ther 2002;9:417-8.
33. Ingle H, Nasim A, Bolia A, Fishwick G, Naylor R, Bell PR, et al.
Subintimal angioplasty of isolated infragenicular vessels in lower limb
ischemia: long-term results. J Endovasc Ther 2002;9:411-6.
34. Korn P, Hoenig SJ, Skillman JJ, Kent KC. Is lower extremity revascu-
larization worthwhile in patients with end-stage renal failure? Surgery
2000;128:472-9.
35. Seeger JM, Pretus HA, Carlson LC, Flynn TC, Ozaki CK, Huber TS.
Potential predictors of outcome in patients with tissue loss who un-
dergo infrainguinal bypass grafting. J Vasc Surg 1999;30:427-35.
JOURNAL OF VASCULAR SURGERY
Volume 42, Number 5 Black et al 93936. Edwards JM, Taylor LM Jr, Porter JM. Limb salvage in end-stage renal
disease (ESRD). Comparison of modern results in patients with and
without ESRD. Arch Surg 1988;123:1164-8.
37. Pomposelli FB, Kansal N, Hamdan AD, Belfield A, SheahanM, Campbell
DR, et al. A decade of experience with dorsalis pedis artery bypass: analysis
of outcome in more than 1000 cases. J Vasc Surg 2003;37:307-15.
38. Gray BH, Sullivan TM, ChildsMB, Young JR, Olin JW.High incidence
of restenosis/reocclusion of stents in the percutaneous treatment oflong-segment superficial femoral artery disease after suboptimal
angioplasty. J Vasc Surg 1997;25:74-83.
39. Schillinger M,MleekuschW, HaumerM, Sabeti S, Ahamdi R, Mianr E.
Angioplasty and elective stenting of de novo versus recurrent lesions:
one year follow-up. J Endovasc Ther 2003;10:288-97.Submitted Jul 15, 2004; accepted Jun 28, 2005.
